Thalidomide influences growth and vasculogenic mimicry channel formation in melanoma
AIMS: To observe the effects of thalidomide on melanoma tumor growth and blood supply patterns in C57 mice. MethodS: Thirty mice inoculated subcutaneously with B16F10 cells were randomly divided into the treatment group and the control group.
Thalidomide was administered once a day at a dose of 200 mg/kg for the treatment group starting on the fifth day after inoculation, and an equivalent volume of 0.5% carboxylmethyl cellulose was administered similarly in the control group. The diameter of the tumors was measured daily after inoculation until the mice were sacrificed on the 19th day.
The different blood supply patterns were counted after immunohistochemical and PAS histochemical double-Staining. VEGF, NF-kappaB, PCNA, MMP-2 and MMP-9 expression in tumor tissue was also assessed.
Results: : The tumor volume(P=0.019) and the number of vasculogenic mimicry(P=0.03) and mosaic vessels(P=0.004) in the treatment group were significantly decreased compared with the control group. VEGF(P=0.004),NF-kappaB(P=0.009), PCNA(P=0.002), MMP-2 (P=0.000), MMP-9(P=0.002) protein expression and MMP-2(P=0.000) and MMP-9(P=0.000) mRNA in the treatment group were significantly lower than those in the control groups.
Conclusions: : Thalidomide inhibits vasculogenic mimicry channel and mosaic vessels formation in melanoma through the regulation of vasculogenic factors, and it can induce necrosis of melanoma cells,which may be related with the NF-kappaB signaling pathway.
Author: Shiwu Zhang, Man Li, Yanjun Gu, Zhiyong Liu, Shaoyan Xu, Yanfeng Cui and Baocun Sun
Credits/Source: Journal of Experimental &Clinical Cancer Research 2008, 27:60
Published on: 2008-11-04
Copyright by the authors listed above - made available via BioMedCentral (Open Access). Please
make sure to read our disclaimer prior to contacting 7thSpace Interactive. To contact our editors, visit our online helpdesk. If you wish submit your own press release, click here.
Social Bookmarking
RETWEET This! | Digg this! | Post to del.icio.us | Post to Furl | Add to Netscape | Add to Yahoo! | Rojo
|
|
